1. The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
- Author
-
Absenger, G, Benhaim, L, Szkandera, J, Zhang, W, Yang, D, Labonte, M J, Pichler, M, Stotz, M, Samonigg, H, Renner, W, Gerger, A, and Lenz, H-J
- Subjects
CYCLINS ,COLON cancer patients ,COLON cancer treatment ,HEALTH outcome assessment ,GENETIC polymorphisms ,CELL cycle ,FLUOROURACIL - Abstract
Recent evidence indicates a potential prognostic and predictive value for germline polymorphisms in genes involved in cell cycle control. We investigated the effect of cyclin D1 (CCND1) rs9344 G>A in stage II/III colon cancer patients and validated the findings in an independent study cohort. For evaluation and validation set, a total of 264 and 234 patients were included. Patients treated with 5-fluorouracil-based chemotherapy, carrying the CCND1 rs9344 A/A genotype had significantly decreased time-to-tumor recurrence (TTR) in univariate analysis and multivariate analysis (hazard ratio (HR) 2.47; 95% confidence interval (CI) 1.16-5.29; P=0.019). There was no significant association between CCND1 rs9344 G>A and TTR in patients with curative surgery alone. In the validation set, the A allele of CCND1 rs9344 G>A remained significantly associated with decreased TTR in univariate and multivariate analyses (HR 1.94; 95% CI 1.05-3.58; P=0.035). CCND1 rs9344 G>A may be a predictive and/or prognostic biomarker in stage II/III colon cancer patients, however, prospective trials are warranted to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF